Reuters logo
BRIEF-Sarepta Therapeutics reports positive results in study
September 6, 2017 / 11:28 AM / 17 days ago

BRIEF-Sarepta Therapeutics reports positive results in study

Sept 6 (Reuters) - Sarepta Therapeutics Inc

* Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053)

* Sarepta Therapeutics Inc - ‍study achieved statistical significance on all primary and secondary biological endpoints​

* Sarepta Therapeutics Inc - ‍study also showed a statistically significant increase in dystrophin immunofluorescence as measured by immunohistochemistry​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below